Sumitomo Pharma achieved sales of 533 billion yen (up 19.1% YoY) in fiscal year 2025, with operating profit significantly increased to approximately 107 billion yen. Overseas sales ratio also expanded to 81.6%, strengthening the future growth foundation.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4506-20260513-02.pdf","jir_short_summary":"Sumitomo Pharma achieved sales of 533 billion yen (up 19.1% YoY) in fiscal year 2025, with operating profit significantly increased to approximately 107 billion yen. Overseas sales ratio also expanded to 81.6%, strengthening the future growth foundation.","jir_summary":"### Business Performance Overview\nIn fiscal year 2025, Sumitomo Pharma\u2019s sales revenue expanded to 4,533 billion yen (up 19.1% YoY), with core operating income reaching 1,059 billion yen (up 145.4%), marking a record high. The overseas sales ratio remained high at 81.6%, with notable growth predominantly in North America. Net income also saw a substantial increase to 1,069 billion yen, enhancing profitability and global competitiveness.\n\n### Future Outlook and Shareholder Impact\nThe company plans to further strengthen overseas expansion, with sustained growth expected in sales and profits driven by new drug development and pipeline progress. R&D expenses are also on the rise, aiming to launch innovative pharmaceuticals. As part of shareholder return strategies, possible dividends and share buybacks are under consideration, positioning the company as an attractive growth investment.","jir_financial_highlights":"Sales Revenue: 4,533\u5104\u5186 (\u524d\u5e74\u6bd4+19.1%)\nNet Income Attributable to Owners of Parent: 1,069\u5104\u5186 (\u524d\u5e74\u6bd4+352.2%)\nCore Operating Income: 1,059\u5104\u5186 (\u524d\u5e74\u6bd4+145.4%)","jir_category":"","jir_hashtags":"#SumitomoPharma, #IRFinancialResults, #JapanStocks","jir_key_figures":"Sales Revenue: 4,533 hundred million yen\uff08\u524d\u5e74\u6bd4+19.1%\uff09\nNet Income Attributable to Owners of Parent: 1,069 hundred million yen\uff08\u524d\u5e74\u6bd4+352.2%\uff09\nCore Operating Income: 1,059 hundred million yen\uff08\u524d\u5e74\u6bd4+145.4%\uff09","jir_meta_title":"\u3010Sumitomo Pharma\u3011Fiscal Year 2025 Financial Results | Sales of 533 billion yen (+19.1% YoY)","jir_meta_description":"Sumitomo Pharma recorded sales of 533 billion yen and net income of approximately 107 billion yen in fiscal year 2025, with significant growth. The overseas ratio is 81.6%, and development of new drugs is progressing, making it a growth-oriented pharmaceutical company.","jir_og_title":"\u3010Sumitomo Pharma\u3011Fiscal Year 2025 Financial Results | Sales of 533 billion yen (+19.1% YoY)","jir_og_description":"Sumitomo Pharma achieved sales of 533 billion yen and net income of about 107 billion yen in fiscal year 2025, continuing growth through overseas expansion and new drug development. A pharmaceutical company with a strong growth trajectory.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Sales Revenue Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"2024\u5e74\u5ea6\\\",\\\"2025\u5e74\u5ea6\\\"],\\\"datasets\\\": [{\\\"label\\\": \\\"Sales (billion yen)\\\",\\\"data\\\": [3988, 4533],\\\"borderColor\\\": \\\"#36A2EB\\\",\\\"fill\\\": false}]} \"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"2024\u5e74\u5ea6\\\",\\\"2025\u5e74\u5ea6\\\"],\\\"datasets\\\": [{\\\"label\\\": \\\"Operating Income (billion yen)\\\",\\\"data\\\": [288, 1073],\\\"borderColor\\\": \\\"#4BC0C0\\\",\\\"fill\\\": false}]} \"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"Japan\\\",\\\"North America\\\",\\\"Asia\\\"],\\\"datasets\\\": [{\\\"data\\\": [924, 3379, 230],\\\"backgroundColor\\\": [\\\"#FF6384\\\",\\\"#36A2EB\\\",\\\"#FFCE56\\\"]}]} \"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Gross Profit Margin\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"2024\u5e74\u5ea6\\\",\\\"2025\u5e74\u5ea6\\\"],\\\"datasets\\\": [{\\\"label\\\": \\\"Gross Profit Margin (%)\\\",\\\"data\\\": [61.4, 56.8],\\\"backgroundColor\\\": \\\"#FF6384\\\"}]} \"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Forecast vs. Actual\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"2025\u5e74\u5ea6\u5b9f\u7e3e\\\"],\\\"datasets\\\": [{\\\"label\\\": \\\"Sales Revenue\\\",\\\"data\\\": [4533],\\\"backgroundColor\\\": \\\"#36A2EB\\\"},{\\\"label\\\": \\\"Net Income\\\",\\\"data\\\": [1069],\\\"backgroundColor\\\": \\\"#4BC0C0\\\"}]} \"}]","ir_related_company":7611,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-48811","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n